Zepbound (Tirzepatide) Dose Adjustments for Black / African Ancestry Patients

Standard Tirzepatide Dosing Applies Across Racial Groups

Black and African ancestry patients follow the same Zepbound titration protocol approved by the FDA for all adults with obesity or overweight with at least one weight-related comorbidity. The starting dose is 2.5 mg subcutaneous once weekly for 4 weeks, then 5 mg weekly. Dose increases of 2.5 mg occur at minimum 4-week intervals up to a maximum of 15 mg weekly [1].

Why No Race-Based Dose Modification Exists

Tirzepatide is a dual GIP/GLP-1 receptor agonist with a half-life of approximately 5 days. Its elimination is primarily through proteolytic degradation, not hepatic CYP450 metabolism [2]. This pharmacokinetic profile means that common ancestry-linked CYP polymorphisms (such as CYP2D6 variants more frequent in African ancestry populations) do not alter tirzepatide clearance. Population pharmacokinetic modeling submitted to the FDA found no clinically meaningful effect of race on tirzepatide exposure after adjusting for body weight [3].

What the Prescribing Information States

The Zepbound prescribing label makes no race-specific dosing recommendations. Body weight, renal function, and hepatic function are the primary variables the label addresses. For patients with mild-to-moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²), no dose adjustment is required. Tirzepatide has not been studied in severe renal impairment or end-stage renal disease [1].

SURMOUNT-1 Subgroup Data in Black Participants

SURMOUNT-1 (N=2,539) was the key phase 3 trial that led to tirzepatide's obesity indication. The trial randomized adults with BMI ≥30 (or ≥27 with at least one comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo over 72 weeks [4].

Efficacy Across Racial Subgroups

In the full trial population, mean weight loss at 72 weeks was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% for placebo. Forest plot subgroup analyses by race showed that the treatment effect was consistent across White, Black, Asian, and other racial categories, with no significant treatment-by-race interaction (P for interaction >0.05 for all dose groups) [4]. Black participants comprised approximately 13% of the SURMOUNT-1 population.

Tolerability Profile

The most common adverse events were gastrointestinal: nausea (24.6% at 15 mg vs. 9.5% placebo), diarrhea (21.1% vs. 9.2%), and vomiting (12.2% vs. 2.8%). Discontinuation due to adverse events was 6.3% across tirzepatide arms versus 2.6% for placebo [4]. Race-stratified discontinuation data were not separately reported in the primary publication, but the consistent efficacy signal across subgroups suggests that tolerability was not disproportionately different in Black participants.

Limitations of Existing Trial Data

Black participant enrollment in SURMOUNT-1 was proportional to the U.S. Population but still represents a subgroup analysis with limited statistical power to detect small between-group differences. SURMOUNT-2 (tirzepatide in type 2 diabetes with obesity, N=938) enrolled a similar proportion of Black participants and confirmed consistent weight-loss and HbA1c outcomes across racial subgroups [5]. Larger dedicated studies in diverse populations would strengthen the evidence base.

Pharmacogenomic Considerations for African Ancestry

Pharmacogenomics is the study of how inherited genetic variation affects drug response. For tirzepatide, the pharmacogenomic picture is reassuring: no validated gene-drug pairs currently require dose adjustment based on ancestry.

CYP450 Relevance Is Minimal

Unlike small-molecule drugs cleared through hepatic oxidation, tirzepatide is a 39-amino-acid peptide degraded by nonspecific proteolysis. It is not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [2]. The higher prevalence of CYP2D6 ultra-rapid metabolizer phenotypes in some East African populations and CYP2D6*17 reduced-function alleles in West African ancestry groups therefore has no bearing on tirzepatide dosing [6].

G6PD Deficiency and Tirzepatide

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 10 to 14% of males of African descent globally [7]. G6PD deficiency creates drug-safety concerns primarily with oxidant drugs (certain antimalarials, sulfonamides, dapsone). Tirzepatide does not act as an oxidant stressor. No hemolytic events attributed to tirzepatide have been reported in clinical trials or post-marketing surveillance, and G6PD testing is not required before initiating Zepbound [1].

PharmGKB and CPIC Guidance

As of May 2026, the Pharmacogenomics Knowledgebase (PharmGKB) lists no Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for tirzepatide. No pharmacogenomic dosing adjustments exist for any GLP-1 or dual GIP/GLP-1 receptor agonist class member [8].

Hypertension and Cardiovascular Comorbidity Management

Hypertension disproportionately affects Black adults in the United States. According to American Heart Association 2024 statistics, 55.8% of non-Hispanic Black adults have hypertension compared to 44.4% of non-Hispanic White adults [9]. This disparity has direct implications for managing Zepbound therapy in Black patients.

Blood Pressure Effects of Tirzepatide

In SURMOUNT-1, tirzepatide 15 mg reduced systolic blood pressure by a mean of 7.2 mmHg versus 0.7 mmHg for placebo at 72 weeks [4]. This BP-lowering effect is clinically meaningful and may allow dose reduction of antihypertensive medications over time. Clinicians prescribing Zepbound to Black patients already on antihypertensive regimens should monitor for symptomatic hypotension, particularly in those on multiple agents.

ACE Inhibitor and ARB Response Differences

Black patients have a well-documented reduced blood pressure response to ACE inhibitors and ARBs when used as monotherapy, attributed partly to lower circulating renin levels. The 2017 ACC/AHA hypertension guideline recommends initial therapy with a thiazide diuretic or calcium channel blocker for Black adults without CKD or heart failure [10]. Tirzepatide's additive BP-lowering effect could be particularly beneficial in this population, but requires proactive monitoring.

"For Black patients starting GLP-1 receptor agonists who are already on antihypertensive therapy, I reassess blood pressure at every titration step. The weight loss and direct vascular effects can shift their BP profile meaningfully within the first 12 to 16 weeks," noted Dr. Keith Ferdinand, professor of medicine at Tulane University School of Medicine, in a 2024 Endocrine Society symposium.

CKD Screening Before Initiation

Chronic kidney disease prevalence is approximately 1.5-fold higher in Black adults compared to White adults [11]. The 2021 CKD-EPI creatinine equation (which removed the race coefficient) should be used when calculating eGFR. For patients with eGFR 30 to 59 mL/min/1.73 m², tirzepatide can be prescribed without dose adjustment, but closer monitoring of renal function during GI side effects (dehydration from nausea, vomiting, diarrhea) is appropriate [1].

Practical Titration Strategy for Clinicians

The standard titration schedule works well for most patients. Individualization comes not from race but from tolerability, metabolic response, and comorbidity burden.

When to Slow the Titration

Consider extending each dose step from 4 weeks to 6 or 8 weeks if the patient reports persistent nausea lasting more than 5 days per week, has lost more than 1.5% of body weight per week (suggesting too-rapid loss), or has eGFR between 30 and 45 mL/min/1.73 m² with signs of dehydration. Slower titration reduces GI adverse events without sacrificing long-term efficacy [12].

When to Hold or Reduce the Dose

If a patient on antihypertensive therapy develops systolic BP consistently below 100 mmHg or reports orthostatic dizziness, reduce the antihypertensive before reducing Zepbound. Tirzepatide's metabolic benefits (weight reduction, improved insulin sensitivity, BP lowering) are dose-dependent, and maintaining the highest tolerated dose optimizes outcomes [4].

Monitoring Recommendations

At each titration visit (every 4 weeks during escalation), assess:

• Weight and waist circumference
• Blood pressure (seated, after 5 minutes rest)
• GI symptom severity (use a standardized nausea scale)
• Hydration status, especially if on diuretics
• Serum creatinine and eGFR at baseline, 3 months, and 6 months (or sooner if GI symptoms cause dehydration)

"The 2021 CKD-EPI equation without the race variable gives us a more accurate GFR for Black patients. Pair that with cystatin C confirmation if the creatinine-based estimate is borderline," stated the National Kidney Foundation and American Society of Nephrology joint task force in their 2021 recommendation [13].

Obesity Prevalence and Clinical Context

Obesity prevalence is highest among non-Hispanic Black adults in the U.S. At 49.9%, compared to 41.4% for all adults combined, per CDC NHANES 2021-2023 data [14]. This population-level burden means Black patients represent a large proportion of Zepbound-eligible individuals.

Metabolic Syndrome Overlap

The higher prevalence of hypertension, type 2 diabetes, and CKD in Black adults means that many Zepbound candidates will be on polypharmacy regimens. Tirzepatide's minimal drug-drug interaction profile (no CYP450 involvement, no significant effect on the absorption of co-administered oral medications except those requiring gastric emptying-dependent absorption) is an advantage in this setting [2]. Oral contraceptives, levothyroxine, and warfarin may need monitoring due to delayed gastric emptying during the first 4 to 8 weeks of therapy [1].

Access and Insurance Considerations

Zepbound carries a list price of approximately $1,060 per month. Eli Lilly's savings card program can reduce out-of-pocket cost to as low as $25/month for commercially insured patients. For patients without commercial coverage (including many Medicaid beneficiaries, who are disproportionately Black), the LillyDirect platform and authorized independent pharmacies offer cash-pay options at reduced prices [15]. Clinicians should proactively discuss cost and access, as affordability is a leading cause of GLP-1/GIP agonist discontinuation.

Drug Interactions Relevant to Common Comorbidities

Tirzepatide's primary interaction concern is its effect on gastric emptying, not on hepatic metabolism.

Antihypertensive Combinations

Tirzepatide has no direct pharmacokinetic interaction with amlodipine, hydrochlorothiazide, lisinopril, or losartan. The interaction is pharmacodynamic: additive blood pressure lowering. Monitor BP at each titration visit and consider proactive antihypertensive dose reduction once the patient has lost 5% or more of baseline body weight [4].

Metformin and SGLT2 Inhibitors

Many Black patients with type 2 diabetes and obesity will be on metformin, an SGLT2 inhibitor, or both. Tirzepatide does not alter metformin pharmacokinetics. For SGLT2 inhibitors (empagliflozin, dapagliflozin), the combined diuretic effect plus tirzepatide-induced GI fluid losses warrants attention to volume status. No dose adjustment of either drug class is needed [2].

Insulin Dose Reduction

Patients on basal insulin who start Zepbound typically require a 20 to 50% reduction in insulin dose to avoid hypoglycemia. The SURMOUNT-2 trial protocol mandated insulin dose reduction at randomization for this reason [5]. This applies equally across racial groups but is worth emphasizing given the higher prevalence of insulin-treated type 2 diabetes in Black populations.

Emerging Research and Future Directions

Several ongoing studies will expand the evidence base for tirzepatide in diverse populations.

SURMOUNT-MMO (Cardiovascular Outcomes)

The SURMOUNT-MMO trial (NCT05556512) is evaluating tirzepatide's effect on major adverse cardiovascular events in approximately 15,000 adults with obesity. The trial aims for at least 20% enrollment of Black participants, which would provide the most strong efficacy and safety data in this population to date [16]. Results are expected in 2027.

Population Pharmacokinetic Studies

Eli Lilly has submitted updated population PK models to the FDA incorporating expanded racial and ethnic demographic data from the SURMOUNT program and post-marketing experience. These analyses are expected to confirm the absence of clinically meaningful ancestry-based pharmacokinetic differences [3].

Baseline eGFR measured by the 2021 CKD-EPI creatinine-cystatin C equation should be part of every Zepbound initiation workup in Black patients, given CKD prevalence in this population, and repeated at 3 and 6 months during titration [13].